

Metabolomics Pipeline Overview

Table of contents


1	Introduction	1
2	Data Distribution	2
3	Sample Analysis — PCA	3
4	Feature Analysis — limma	4
5	Supervised Analysis — sparse PLS-DA	5
6	Upcoming	11

1 Introduction

A basic analysis pipeline in R for untargeted LC-MS metabolomics, including quality control, normalization, PCA overview of sample behavior, and differential feature analysis with linear models. The data are panels of untargeted LC-MS features from positive and negative ionization mode runs, such as metabolites measured from tissue, stool samples, or microbial cultures. In this hypothetical scenario, the data have been structured to resemble samples belonging to control subjects, one of two treatments (tr1 or tr2), or a dual-treatment group (tr1+tr2). The pipeline demonstrates a conventional approach to characterizing metabolomic differences among these groups.


2 Data Distribution

The LC-MS intensities of metabolomics data typically skew to the right. Data normalization is required to improve comparability across samples and help stabilize variance before actual analysis can begin. The figure below demonstrates how median normalization reduces between-sample differences in overall intensity while preserving the underlying variability that's of interest in the data. The data are also transformed into a log₂ scale to reduce domination by extreme values and bring the data closer to normality.



3 Sample Analysis — PCA


To gauge the overall structure of the metabolomic profiles (samples), a Principal Components Analysis is used. The median-normalized, log₂-transformed intensities are next centered and scaled, then decomposed into a set of orthogonal principal components that capture the dominant sources of variance in the dataset.



Principal component (PC) 1 illustrates a divide amongst the samples based on the treatment group, with controls and tr1 contrasted from tr2 and the dual-treatment (tr1+tr2). Additionally, PC 1 captures 35.7% of the variance in the data for the negative-mode intensities and 29.11% for the positive-mode intensities, meaning the treatment variable has substantial influence on the overall data structure (as might be expected). PC 2 does not appear to highlight any meaningful secondary structure in the data.


4 Feature Analysis — limma

To evaluate the underlying feature fluctuations responsible for the observed sample differences, linear models for microarrays (limma) were applied to the median-normalized, log2-transformed intensities. This approach tests each LC-MS feature for differential abundance across treatment groups while controlling the false discovery rate using multiple-testing correction. The figures below depict the differentially abundant features for each pairwise comparison, highlighting metabolites that most strongly distinguish the control, single-treatment (tr1, tr2), and dual-treatment (tr1+tr2) conditions.




5 Supervised Analysis — sparse PLS-DA

(sparse Partial Least Squares Discriminant Analysis)




sparse PLS-DA pos-mode




(description of sample plots) (introduce the means of exploring LC-MS peak behaviors through plotVar and plotLoadings outputs)

sparse PLS-DA comp1 neg-mode




sparse PLS-DA comp2 | neg-mode




(explanatory text for neg-mode sPLSDA)

sparse PLS-DA comp1 pos-mode



sparse PLS-DA comp2 | pos-mode



(explanatory text for pos-mode sPLSDA)

6 Upcoming

- Add table containing differential feature counts per contrast and percent-of-features exhibiting significant differences.
- Incorporate more methodology discussion
- Putative feature annotation using KEGG (example workflow).